These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26848792)

  • 1. Extrapyramidal Symptoms During Risperidone Maintenance Treatment in Schizophrenia: A Prospective, Multicenter Study.
    Bo QJ; Li XB; Wang ZM; Li AN; Ma X; Wang CY
    J Clin Psychopharmacol; 2016 Apr; 36(2):125-9. PubMed ID: 26848792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia.
    Bo Q; Dong F; Li X; Wang Z; Ma X; Wang C
    BMC Psychiatry; 2016 Nov; 16(1):386. PubMed ID: 27829454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
    Novick D; Haro JM; Bertsch J; Haddad PM
    J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.
    Miller CH; Mohr F; Umbricht D; Woerner M; Fleischhacker WW; Lieberman JA
    J Clin Psychiatry; 1998 Feb; 59(2):69-75. PubMed ID: 9501888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrapyramidal symptoms in patients treated with risperidone.
    Simpson GM; Lindenmayer JP
    J Clin Psychopharmacol; 1997 Jun; 17(3):194-201. PubMed ID: 9169965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
    Timdahl K; Carlsson A; Stening G
    Hum Psychopharmacol; 2007 Jul; 22(5):315-25. PubMed ID: 17542047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment for schizophrenia.
    Xiang YT; Wang CY; Ungvari GS; Kreyenbuhl JA; Chiu HF; Lai KY; Lee EH; Bo QJ; Dixon LB
    Pharmacopsychiatry; 2011 Jun; 44(4):135-41. PubMed ID: 21710403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone.
    Kopala LC; Good KP; Honer WG
    J Clin Psychopharmacol; 1997 Aug; 17(4):308-13. PubMed ID: 9241011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E; Valsecchi P; Parrinello G;
    Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.
    Zalsman G; Carmon E; Martin A; Bensason D; Weizman A; Tyano S
    J Child Adolesc Psychopharmacol; 2003; 13(3):319-27. PubMed ID: 14642020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia.
    Azorin JM; Spiegel R; Remington G; Vanelle JM; Péré JJ; Giguere M; Bourdeix I
    Am J Psychiatry; 2001 Aug; 158(8):1305-13. PubMed ID: 11481167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database.
    Fleischhacker WW; Lemmens P; van Baelen B
    Pharmacopsychiatry; 2001 May; 34(3):104-10. PubMed ID: 11434401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
    Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
    Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.